TORONTO, June 16,
2023 /CNW/ - HLS Therapeutics Inc. ("HLS" or the
"Company") (TSX: HLS), a pharmaceutical company focused on central
nervous system and cardiovascular markets, announces voting results
from its Annual Meeting of Shareholders held in a virtual format on
June 16, 2023.
A total of 28,831,784 Common Shares, or 89.12% of the total
Common Shares issued and outstanding, were voted based on proxies
and votes received at the meeting. Details of the voting by
individual director were as follows:
Name of
Nominee
|
Votes
Cast
FOR
|
% of Vote Cast
FOR
|
Votes
WITHHELD
|
% of Votes
WITHHELD
|
Greg Gubitz
|
22,455,427
|
79.91
|
5,644,061
|
20.09
|
Rodney Hill
|
25,391,740
|
90.36
|
2,707,748
|
9.64
|
Laura Brege
|
23,482,483
|
83.57
|
4,617,005
|
16.43
|
John Welborn
|
27,129,959
|
96.55
|
969,529
|
3.45
|
Norma
Beauchamp
|
23,498,085
|
83.63
|
4,601,403
|
16.38
|
Kyle Dempsey
|
26,205,959
|
93.26
|
1,893,529
|
6.74
|
Craig
Millian
|
27,133,127
|
96.56
|
966,361
|
3.44
|
Christian
Roy
|
27,145,091
|
96.60
|
954,397
|
3.40
|
HLS also confirms that shareholders approved the appointment of
Ernst & Young LLP as the Company's auditors with 28,796,380
votes (99.88%) cast "for" and 35,404 votes (0.12%) "withheld".
Shareholders also approved certain proposed amendments to the
Corporation's Stock Option Plan, and approved the unallocated
options thereunder, with 23,405,117 votes (83.29%) cast "for" and
4,694,371 votes (16.71%) cast "against".
ABOUT HLS THERAPEUTICS INC.
Formed in 2015, HLS is a pharmaceutical company focused on the
acquisition and commercialization of late-stage development,
commercial stage promoted and established branded pharmaceutical
products in the North American markets. HLS's focus is on products
targeting the central nervous system and cardiovascular therapeutic
areas. HLS's management team is composed of seasoned pharmaceutical
executives with a strong track record of success in these
therapeutic areas and at managing products in each of these
lifecycle stages. For more information visit:
www.hlstherapeutics.com
SOURCE HLS Therapeutics Inc.